CN110812407A - Sihuang dysentery stopping micro-capsule and preparation method thereof - Google Patents
Sihuang dysentery stopping micro-capsule and preparation method thereof Download PDFInfo
- Publication number
- CN110812407A CN110812407A CN201911155296.3A CN201911155296A CN110812407A CN 110812407 A CN110812407 A CN 110812407A CN 201911155296 A CN201911155296 A CN 201911155296A CN 110812407 A CN110812407 A CN 110812407A
- Authority
- CN
- China
- Prior art keywords
- parts
- dysentery stopping
- capsule
- sihuang
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001848 dysentery Diseases 0.000 title claims abstract description 63
- 239000003094 microcapsule Substances 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 38
- 239000000284 extract Substances 0.000 claims abstract description 26
- 150000004676 glycans Chemical class 0.000 claims abstract description 25
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 25
- 239000005017 polysaccharide Substances 0.000 claims abstract description 25
- 241001061264 Astragalus Species 0.000 claims abstract description 23
- 235000006533 astragalus Nutrition 0.000 claims abstract description 23
- 210000004233 talus Anatomy 0.000 claims abstract description 23
- 241000334160 Isatis Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 12
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 4
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 4
- 241000207929 Scutellaria Species 0.000 claims abstract description 4
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract 2
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 17
- 239000008118 PEG 6000 Substances 0.000 claims description 16
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 16
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 16
- 241000037740 Coptis chinensis Species 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 239000010231 banlangen Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 241000218202 Coptis Species 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 244000144977 poultry Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 14
- 239000000463 material Substances 0.000 abstract description 8
- 235000019640 taste Nutrition 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 235000019658 bitter taste Nutrition 0.000 abstract description 2
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 235000013330 chicken meat Nutrition 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 19
- 241000219061 Rheum Species 0.000 description 11
- 241000218691 Cupressaceae Species 0.000 description 10
- 240000004534 Scutellaria baicalensis Species 0.000 description 10
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 10
- 241000157835 Gardenia Species 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 8
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 8
- 229960003321 baicalin Drugs 0.000 description 8
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 206010059866 Drug resistance Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000006996 mental state Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 241000252983 Caecum Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010071301 Perihepatitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of chicken colibacillosis treatment, and discloses a Sihuang dysentery stopping microcapsule which comprises the following components: soft extract, emulsifier and astragalus polysaccharide; the thick paste is prepared from the following raw materials: coptis root, phellodendron bark, rhubarb, scutellaria root, isatis root, liquorice, honeysuckle and gardenia. The invention adopts the western medicine preparation of the traditional Chinese medicine, has simple preparation process, does not need to be dried again, saves the production cost, can fully extract the effective components, can cover the inherent bitter taste of the traditional Chinese medicine of the medicine by adding the auxiliary materials to prepare the micro-capsule, improves the mouth feel, and has good dissolubility and high bioavailability. The Sihuang dysentery stopping micro-capsule has the advantages of reasonable proportion, convenient operation, good content uniformity, good stability, high yield, good taste and good treatment effect.
Description
Technical Field
The invention relates to the field of chicken colibacillosis treatment, and particularly relates to a Sihuang dysentery stopping microcapsule and a preparation method thereof.
Background
Colibacillosis in chickens is an acute and chronic bacterial infectious disease of various chickens caused by pathogenic escherichia coli, can occur in various varieties and chickens of various ages, and seriously affects the development of the chicken industry. In recent years, with the continuous scale development of the breeding industry, a plurality of farmers increase the breeding amount blindly, which causes the deterioration of the breeding environment. The chicken can be prevented and treated by medicines after group outbreak, the commonly used medicines are mostly antibiotic medicines, but in recent years, the colibacillus is very easy to generate drug resistance to the medicines, and antibiotics such as penicillin, streptomycin, terramycin, tetracycline and the like have almost no treatment effect. The chloramphenicol, the gentamicin, the norfloxacin and the neomycin have better treatment effect. However, strains which have drug resistance to these drugs have appeared and are increasing, which causes colibacillosis to appear an increasing trend, and causes great economic loss for breeding production. Colibacillosis in chicken is an infectious disease with complex disease conditions, and can be regarded as virus immersion, lung and stomach heat and blood stasis and qi stagnation according to the dialectical demonstration of Chinese veterinarian, and the treatment is suitable for clearing heat and removing toxicity, activating blood and dissipating blood stasis. The traditional Chinese medicine, in particular to the traditional Chinese medicine granules extracted and processed by the modern technology, becomes the development direction of veterinary medicines. The Sihuang Zhili granule is a Chinese medicinal granule prepared by 6 Chinese medicaments of coptis root, phellodendron bark, rhubarb, scutellaria root, isatis root, liquorice root and the like through the processes of decoction, filtration, concentration, granulation, drying and the like, and has the functions of clearing heat, purging pathogenic fire and stopping dysentery. However, the existing Sihuang dysentery stopping granules show drug resistance; in addition, the dissolution is slow and the palatability is poor when the composition is clinically used.
Therefore, the development of the tetra-yellow dysentery stopping micro-capsule with good palatability, high efficiency and low drug resistance to prevent and treat the chicken colibacillosis is urgently needed.
Disclosure of Invention
The invention aims to provide a Sihuang dysentery stopping microcapsule and a preparation method thereof, and the Sihuang dysentery stopping microcapsule has the advantages of reasonable proportion, low drug resistance, good content uniformity, good stability, high yield, good taste and good treatment effect.
In order to achieve the purpose, the invention adopts the technical scheme that:
a Sihuang dysentery stopping microcapsule comprises the following components: soft extract, emulsifier and astragalus polysaccharide; the thick paste is prepared from the following raw materials: coptis root, phellodendron bark, rhubarb, scutellaria root, isatis root, liquorice, honeysuckle and gardenia.
Preferably, the Sihuang dysentery stopping microcapsule comprises the following components in parts by mass: 10-30 parts of thick paste, 50-65 parts of emulsifier and 10-15 parts of astragalus polysaccharide; the thick paste is prepared from the following raw materials in parts by mass: 300 parts of coptis chinensis 200-.
Preferably, the emulsifier is selected from one or two of PEG4000 and PEG 6000.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water, filtering, and concentrating to obtain soft extract;
(2) mixing emulsifier and astragalus polysaccharide, heating and stirring;
(3) cooling, adding the soft extract while stirring to obtain mixture;
(4) granulating the mixture, and sieving to obtain the capsule.
Preferably, the number of times of decocting with water in step (1) is 2-5, and the time of decocting with water is: the first time of decoction is 2-3 hours, and the second time of decoction is 1-2 hours.
Preferably, the concentration process in step (1) is as follows: concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35.
Preferably, the temperature of the temperature rise in the step (2) is 75-90 ℃.
Preferably, the temperature reduction in the step (2) is to reduce the temperature to 65-75 ℃.
Preferably, the equipment used for granulating in step (3) is a spray granulator.
Preferably, the rotating speed of the spray granulator in the step (3) is 300-.
Preferably, the step (3) of sieving obtains the four-yellow dysentery stopping microcapsule with the particle size of 200-.
An application of Sihuang dysentery stopping microcapsule in preparing medicine for treating and preventing livestock and poultry colibacillosis is provided.
The astragalus polysaccharide is an extract of astragalus root, one of the most representative of a plurality of bioactive polysaccharides, is a typical representative of a Chinese herbal immunopotentiator, has the functions of enhancing the immunity of organisms, resisting viruses, tumors, delaying senescence, resisting oxidation, resisting stress, regulating blood sugar and the like, can improve the taste, mask the unpleasant odor of medicaments, increase the appetite of animals, improve the immunity of the animals, strengthen the animal body and improve the disease prevention capability, and particularly has more effect when the disease resistance of the animals is reduced due to stress such as beak breaking, inoculation, group transfer, heat stress and the like.
Colibacillosis in chicken is an infectious disease with complex disease conditions, and can be regarded as virus immersion, lung and stomach heat and blood stasis and qi stagnation according to the dialectical demonstration of Chinese veterinarian, and the treatment is suitable for clearing heat and removing toxicity, activating blood and dissipating blood stasis. The damp-heat can not be removed by using antibiotics only. The formula takes the coptis chinensis, the golden cypress, the rhubarb, the isatis root and the scutellaria baicalensis as monarch drugs, has the effects of clearing heat, drying dampness, stopping dysentery, removing internal factors of damp heat, enabling the environment in an intestinal tract to be normal, and has the effects of resisting virus and sterilizing. Honeysuckle and gardenia are used as ministerial drugs, wherein the honeysuckle has the functions of clearing away heat and toxic materials and dispelling wind and heat; gardenia jasminoides ellis clears fire and toxic materials, clears heat and induces diuresis, and cools blood. The astragalus polysaccharide in the astragalus is the most representative of a plurality of bioactive polysaccharides, and has the functions of enhancing body immunity, resisting virus, resisting tumor, delaying senility, resisting oxidation, resisting stress, regulating blood sugar and the like as a typical representation of a Chinese herbal medicine immunopotentiator. The liquorice is used as a messenger drug, and has the effects of tonifying spleen and qi, relieving cough and moistening lung, relieving urgency and detoxifying, and harmonizing various drugs. The traditional Chinese medicine provided by the invention can adjust the physiological condition of the organism besides resisting virus and sterilizing, so as to treat both symptoms and root causes, and effectively utilize the nature, taste, meridian tropism and functional indication of the traditional Chinese medicine.
The beneficial technical effects of the invention are as follows:
the invention adopts the western medicine preparation of the traditional Chinese medicine, has simple preparation process, does not need to be dried again, saves the production cost, can fully extract the effective components, can cover the inherent bitter taste of the traditional Chinese medicine of the medicine by adding the auxiliary materials to prepare the micro-capsule, improves the mouth feel, and has good dissolubility and high bioavailability.
The Sihuang dysentery stopping micro-capsule has the advantages of reasonable proportion, convenient operation, good content uniformity, good stability, high yield, good taste and good treatment effect.
1) The Sihuang dysentery stopping micro-capsule provided by the invention has the effects of clearing heat, drying dampness, detoxifying, stopping dysentery, strengthening spleen and stomach, helping digestion and being safe to use by combining various traditional Chinese medicinal materials.
2) The optimal proportion of the traditional Chinese medicines is combined and astragalus polysaccharide is added as a modifier, so that the taste can be improved, the unpleasant smell of the medicines can be covered, the compliance of livestock and poultry to the medicines can be increased, the appetite of animals can be increased, the immunity of the animals can be improved, and the traditional Chinese medicines are good in dissolubility and high in bioavailability.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail by examples below. It should be understood, however, that the description herein of specific embodiments is only intended to illustrate the invention and not to limit the scope of the invention.
Example 1
A Sihuang dysentery stopping microcapsule comprises the following components in parts by weight:
28 parts of thick paste, 45 parts of PEG4000, 12 parts of PEG6000 and 15 parts of astragalus polysaccharide;
the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice, 100 parts of honeysuckle and 100 parts of gardenia.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;
(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, cooling to 70 deg.C, adding the soft extract under stirring to obtain mixture;
(3) adding the mixture into a spray granulator with the rotation speed of 350r/min for granulation, and sieving to obtain the Sihuang dysentery stopping micro-capsule.
Example 2
A Sihuang dysentery stopping microcapsule comprises the following components in parts by weight:
25 parts of thick paste, 45 parts of PEG4000, 15 parts of PEG6000 and 15 parts of astragalus polysaccharide;
the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice, 100 parts of honeysuckle and 100 parts of gardenia.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;
(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, cooling to 70 deg.C, adding the soft extract under stirring to obtain mixture;
(3) adding the mixture into a spray granulator with the rotation speed of 350r/min for granulation, and sieving to obtain the Sihuang dysentery stopping micro-capsule.
Example 3
A Sihuang dysentery stopping microcapsule comprises the following components in parts by weight:
20 parts of thick paste, 45 parts of PEG4000, 15 parts of PEG6000 and 20 parts of astragalus polysaccharide;
the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice, 100 parts of honeysuckle and 100 parts of gardenia.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;
(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, cooling to 70 deg.C, adding the soft extract under stirring to obtain mixture;
(3) adding the mixture into a spray granulator with the rotation speed of 350r/min for granulation, and sieving to obtain the Sihuang dysentery stopping micro-capsule.
Comparative example 1
A Sihuang dysentery stopping microcapsule comprises the following components in parts by weight:
30 parts of thick paste, 50 parts of PEG4000 and 20 parts of PEG 6000; the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice, 100 parts of honeysuckle and 100 parts of gardenia.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;
(2) mixing PEG4000 and PEG6000, heating to 80 deg.C, stirring, cooling to 70 deg.C, and adding the soft extract while stirring to obtain mixture;
(3) adding the mixture into a spray granulator with the rotation speed of 350r/min for granulation, and sieving to obtain the Sihuang dysentery stopping micro-capsule.
Comparative example 2
A Sihuang dysentery stopping microcapsule comprises the following components in parts by weight:
28 parts of thick paste, 45 parts of PEG4000, 12 parts of PEG6000 and 15 parts of astragalus polysaccharide;
the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice, 100 parts of honeysuckle and 100 parts of gardenia.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;
(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, cooling to 50 deg.C, and adding the soft extract under stirring to obtain mixture;
(3) adding the mixture into a spray granulator with the rotation speed of 350r/min for granulation, and sieving to obtain the Sihuang dysentery stopping micro-capsule.
Comparative example 3
A Sihuang dysentery stopping microcapsule comprises the following components in parts by weight:
28 parts of thick paste, 45 parts of PEG4000, 12 parts of PEG6000 and 15 parts of astragalus polysaccharide;
the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice, 100 parts of honeysuckle and 100 parts of gardenia.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;
(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, heating to 98 deg.C, and adding the soft extract under stirring to obtain mixture;
(3) adding the mixture into a spray granulator with the rotation speed of 350r/min for granulation, and sieving to obtain the Sihuang dysentery stopping micro-capsule.
Comparative example 4
A Sihuang dysentery stopping microcapsule comprises the following components in parts by weight:
28 parts of thick paste, 45 parts of PEG4000, 12 parts of PEG6000 and 15 parts of astragalus polysaccharide;
the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root and 100 parts of liquorice.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis and Glycyrrhrizae radix in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;
(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, cooling to 70 deg.C, adding the soft extract under stirring to obtain mixture;
(3) adding the mixture into a spray granulator with the rotation speed of 350r/min for granulation, and sieving to obtain the Sihuang dysentery stopping micro-capsule.
Comparative example 5
The Sihuang dysentery stopping granules comprise the following components in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice and 10-30 parts of auxiliary materials; the auxiliary material is selected from sucrose and dextrin.
A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:
(1) decocting coptis chinensis, golden cypress, rheum officinale, scutellaria baicalensis, isatis root and liquorice in water for 2 hours for the first time and 1 hour for the second time, mixing decoctions, filtering, concentrating, and concentrating the filtrate to obtain a thick paste with the relative density of 1.32-1.35;
(2) adding sucrose and dextrin, granulating, and drying to obtain SIHUANGZHILI granule.
Test example 1: the content uniformity of the drug of the invention and the content uniformity of the drug of the common dosage form were measured, and the smaller the content uniformity, the better the content uniformity, comparing the content uniformity of baicalin in example 1 and example 5, the results are shown in table 1.
TABLE 1 content uniformity of baicalin
Example 1 the content uniformity of three batches of drug was: 1.8, 2.2 and 1.8, while the uniformity of the content of the three batches of the drug in the comparative example 5 is respectively 9.2, 11.2 and 10.0, the data show that the uniformity of the content of the drug baicalin found by the method is better than that of the drug baicalin of the invention of the common dosage form, and the content of the baicalin is required to be more than 100 percent of the marked amount according to the quality standard of the Sihuang dysentery stopping granules, namely, the content of the drug in the three batches of the common dosage form in the comparative example 5 is unqualified.
Test example 2: detecting the yield of the Sihuang dysentery stopping micro-capsule and determining the production process thereof.
1 purpose of the test: the optimal production process is determined by detecting the yield of the Sihuang dysentery stopping micro-capsule provided by the invention, so that the benefit is maximized.
2 test drugs: test products: tetrahuang dysentery stopping microcapsules (prepared according to example 1 and comparative examples 1-3).
3, test results: the yields of example 1 and comparative example 1 are best; comparative example 2 because the material temperature is too low, the mobility is bad, apt to stop up pipeline and shower nozzle, the yield is low; comparative example 3 the results are shown in table 2, in which the particles are agglomerated and the yield is low because the surface temperature of the particles is high without being rapidly cooled.
TABLE 2 recovery of Sihuang dysentery stopping micro-capsules
Test example 3: stability test of Sihuang Zhili micro-capsule (accelerated test)
1 purpose of the test: the stability of the Sihuang dysentery stopping micro-capsule provided by the invention is verified by detecting the content change of baicalin under an accelerated test condition.
2 test drugs: test products: tetra-yellow dysentery-stopping microcapsules (prepared according to examples 1 and 2, 3 batches each); all the raw materials are commercial products.
3, test method:
the test was carried out by referring to accelerated test measurement in stability of the first edition of pharmacopoeia of the people's republic of China 2015. And (3) packaging according to a market, placing for 6 months under the conditions that the temperature is 40 +/-2 ℃ and the relative temperature is 70 +/-5%, monitoring the temperature and the humidity in real time, sampling once at 1 month, 2 months, 3 months and 6 months in the test period, detecting the content of the baicalin, and comparing with a zero-hour sample.
4, test results:
under the condition of accelerated test, the content of baicalin in the four-yellow dysentery stopping micro-capsule is detected, and the test result is shown in table 3. The results show that: the content of the tetra-yellow dysentery stopping microcapsule (examples 1 and 2 of the invention) is stable and is more than 100% in the examples 1 and 2 under the condition of an accelerated test, and the test result shows that the tetra-yellow dysentery stopping microcapsule of the invention has high stability.
TABLE 3 accelerated test results of Sihuang dysentery stopping micro-capsules
Test example 4: clinical test of 'Sihuang' dysentery stopping micro-capsule
1 purpose of the test: the Sihuang dysentery stopping micro-capsule provided by the invention has the effect of treating chicken colibacillosis by detecting.
2 test drugs: test products: tetra-yellow dysentery stopping granules (microcapsules) (prepared according to example 1, comparative example 1 and comparative example 4, 1 batch each); all the raw materials are commercial products.
3, test method:
the targeted chicken, sick chicken, depressed spirit, loose feather, anorexia, and abominable. Some sick chickens have diarrhea, and feathers below cloaca are moist and dirty and sticky. Lameness. Ophthalmia, some with neurological symptoms. Chronic emaciation, slow growth, arthritic inflammation, pericarditis visualized by autopsy, hydropericardium, pericardial morbid turbidity, adhesion of internal exudates to myocardium, and cellulose perihepatitis. It shows hepatomegaly, exudation of cellulosic exudates from the liver surface, fibrinous bronchiolitis, turbid air sac, and cellulosic exudates. Granuloma, which is mainly produced in the duodenum, caecum, mesentery and liver, produces colibacillus granuloma, follicular membrane is congested and deformed, and the follicle is reddish brown or dark brown. Congestion and bleeding of the fallopian tube. Cock testis hyperemia, dyspareunia congestion, swelling, and colibacillosis were noted, and the targeted chickens were divided into four groups of 100 chickens each and were fed without the lutetium-containing diarrhea-relieving microcapsule blank test, and were fed with the dose of each of example 1, comparative example 1, and comparative example 4, mixed with the dose of each, for 10 days.
4, test results:
the results are shown in Table 4.
TABLE 4
The blank group found that targeted chickens had a mortality rate of 98% within 10 days of feeding; example 1 after feeding targeted chickens for 10 days, the mental state is good, the diet is normal, the feces are normal, the survival rate is as high as 99%, the duodenum, the caecum, the mesentery and the liver of the targeted chickens are all normal through cesarean examination, and no escherichia coli exists, which indicates that the tetra-yellow dysentery stopping microcapsules prepared in example 1 have the effect of treating the colibacillosis. After the targeted chicken in the comparative example 1 is fed for 10 days, the mental state is good, the diet is normal, the feces are normal, and the survival rate reaches 95%, but the daily feed intake of the chicken in the example 1 is about 10g more than that of the chicken in the comparative example 1, which shows that the addition of the polysaccharides from Huang's republic of food can increase the appetite; the targeted chicken of comparative example 4 was fed for 10 days and had good mental status, normal diet and normal feces, but had a survival rate of only 90% and found 3 chickens with coliform bacteria. The experiment proves that the survival rate of the example 1 is higher than that of the comparative example 4, which shows that the effect of treating colibacillosis is improved by adding honeysuckle and gardenia, and the drug resistance is low.
After the four-yellow dysentery stopping micro-capsule is used for drug administration, the mental state of sick chickens is good, the feces are normal, the feed intake is increased, and all diseases disappear.
Claims (10)
1. The Sihuang dysentery stopping microcapsule is characterized by comprising the following components: soft extract, emulsifier and astragalus polysaccharide; the thick paste is prepared from the following raw materials: coptis root, phellodendron bark, rhubarb, scutellaria root, isatis root, liquorice, honeysuckle and gardenia.
2. The tetra yellow dysentery stopping microcapsule according to claim 1, which is characterized by comprising the following components in parts by mass: 10-30 parts of thick paste, 50-65 parts of emulsifier and 10-15 parts of astragalus polysaccharide; the thick paste is prepared from the following raw materials in parts by mass: 300 parts of coptis chinensis 200-.
3. The tetra yellow dysentery stopping microcapsule according to claim 1 or 2, wherein the emulsifier is one or two selected from PEG4000 and PEG 6000.
4. A process for preparing a tetra yellow dysentery stopping microcapsule according to any one of claims 1 to 3, which comprises the steps of:
(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water, filtering, and concentrating to obtain soft extract;
(2) mixing emulsifier and Astragalus polysaccharides, heating and stirring, cooling, and adding the soft extract while stirring to obtain mixture;
(3) granulating the mixture, and sieving to obtain the capsule.
5. The method according to claim 4, wherein the concentration in step (1) is carried out by: concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35.
6. The method of claim 4, wherein the stirring of step (2) is performed at 75 ℃ to 90 ℃.
7. The method for preparing the nano-particles according to claim 4, wherein the temperature reduction in the step (2) is to reduce the temperature to 65-75 ℃.
8. The method according to claim 4, wherein the granulating in step (3) is carried out by using a spray granulator.
9. The preparation method according to claim 4, wherein the rotation speed of the spray granulator in step (3) is 300-350 r/min.
10. The use of the tetra-yellow dysentery stopping microcapsule according to any one of claims 1-3 in the preparation of a medicament for treating and preventing colibacillosis in livestock and poultry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911155296.3A CN110812407A (en) | 2019-11-22 | 2019-11-22 | Sihuang dysentery stopping micro-capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911155296.3A CN110812407A (en) | 2019-11-22 | 2019-11-22 | Sihuang dysentery stopping micro-capsule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110812407A true CN110812407A (en) | 2020-02-21 |
Family
ID=69558464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911155296.3A Pending CN110812407A (en) | 2019-11-22 | 2019-11-22 | Sihuang dysentery stopping micro-capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110812407A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113181260A (en) * | 2021-04-22 | 2021-07-30 | 广西壮族自治区水产技术推广站 | Chinese herbal medicine composition for preventing and treating white eye disease of tortoise, preparation method and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590139A (en) * | 2008-05-30 | 2009-12-02 | 天津生机集团股份有限公司 | A kind of preparation method of preventing and treating the Chinese medicine compound four yellow dysentery stopping preparations of livestock and poultry intestinal canal diseases |
| CN101816724A (en) * | 2009-11-16 | 2010-09-01 | 天津瑞贝特科技发展有限公司 | Effervescent traditional Chinese medicine composition having dampness removing and diarrhea-relieving function and preparation method thereof |
| CN101947270A (en) * | 2010-10-14 | 2011-01-19 | 郑州后羿制药有限公司 | Aerosol for preventing and controlling pullorum disease and preparation method thereof |
| CN102232974A (en) * | 2010-05-07 | 2011-11-09 | 烟台绿叶动物保健品有限公司 | Preparation method of Chinese medicinal granule for poultry |
| CN109172599A (en) * | 2018-09-10 | 2019-01-11 | 佛山市正典生物技术有限公司 | Microcapsule formulation and preparation method thereof for preventing and treating chicken leucocyte protozoon |
| CN109568290A (en) * | 2018-12-14 | 2019-04-05 | 佛山市正典生物技术有限公司 | A kind of Fenbendazole micro-capsule and preparation method thereof |
-
2019
- 2019-11-22 CN CN201911155296.3A patent/CN110812407A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590139A (en) * | 2008-05-30 | 2009-12-02 | 天津生机集团股份有限公司 | A kind of preparation method of preventing and treating the Chinese medicine compound four yellow dysentery stopping preparations of livestock and poultry intestinal canal diseases |
| CN101816724A (en) * | 2009-11-16 | 2010-09-01 | 天津瑞贝特科技发展有限公司 | Effervescent traditional Chinese medicine composition having dampness removing and diarrhea-relieving function and preparation method thereof |
| CN102232974A (en) * | 2010-05-07 | 2011-11-09 | 烟台绿叶动物保健品有限公司 | Preparation method of Chinese medicinal granule for poultry |
| CN101947270A (en) * | 2010-10-14 | 2011-01-19 | 郑州后羿制药有限公司 | Aerosol for preventing and controlling pullorum disease and preparation method thereof |
| CN109172599A (en) * | 2018-09-10 | 2019-01-11 | 佛山市正典生物技术有限公司 | Microcapsule formulation and preparation method thereof for preventing and treating chicken leucocyte protozoon |
| CN109568290A (en) * | 2018-12-14 | 2019-04-05 | 佛山市正典生物技术有限公司 | A kind of Fenbendazole micro-capsule and preparation method thereof |
Non-Patent Citations (8)
| Title |
|---|
| 周克振主编: "《中医类方妙用新编》", 31 July 2010, 湖南科学技术出版社 * |
| 姚静编: "《药用辅料应用指南》", 31 August 2011, 中国医药科技出版社 * |
| 戴卫红，丛月珠: "复方黄连解毒微囊的制备", 《中国中医急症》 * |
| 王世宇主编: "《药用辅料学》", 30 April 2019, 中国中医药出版社 * |
| 赵建平，张素梅编: "《兽用中药方剂精编》", 30 September 2011, 中原农民出版社 * |
| 邢兰君: "中西结合治疗蛋雏鸡大肠杆菌并发传染性法氏囊病", 《中兽医学杂志》 * |
| 马文奎: "中西医结合诊治瘤头鸭顽固性大肠杆菌病", 《上海畜牧兽医通讯》 * |
| 鲜敏: "我国兽用药物制剂生产企业的现状与展望", 《中国优秀硕士学位论文全文数据库 经济与管理科学辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113181260A (en) * | 2021-04-22 | 2021-07-30 | 广西壮族自治区水产技术推广站 | Chinese herbal medicine composition for preventing and treating white eye disease of tortoise, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614288B (en) | Chinese herbal microecological preparation for preventing and treating chicken Colibacillosis and preparation method thereof | |
| CN101664421B (en) | A traditional Chinese medicine biological preparation for preventing and treating livestock and poultry diarrhea, its preparation method and feed | |
| CN102090506B (en) | Compound Chinese medicinal herbal additive for promoting growth of cadpigs and preparation method thereof | |
| CN102940722B (en) | A kind ofly treat Chinese medicine composition of fowl bacterial disease and preparation method thereof | |
| CN102078522A (en) | Chinese medicine composition for treating enterovirus syndrome in chicken | |
| CN102319297B (en) | Traditional Chinese veterinary medicine used for treating livestock, poultry and fish diseases | |
| CN103006892A (en) | Medicine composition for preventing and treating porcine viral diseases, and premix and batch with composition | |
| CN104739960B (en) | Stomach antibacterial combination, the stomach antibacterials containing said composition and preparation | |
| CN108310046B (en) | A kind of targeting microcapsules of total alkaloids of Sophora japonica and preparation method thereof | |
| CN110812407A (en) | Sihuang dysentery stopping micro-capsule and preparation method thereof | |
| CN101961468B (en) | Traditional Chinese medicinal composition for preventing and treating porcine respiratory syndrome and application thereof | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN102813713B (en) | Rhizoma dryopteris crassirhizomae and fructus crataegi composition, preparation method and application of composition | |
| CN101524479B (en) | Medicine for curing avian infectious bronchitis | |
| CN106389562A (en) | Pudilan Xiaoyan granules, preparation method thereof, and product quality control method | |
| CN112451589B (en) | A kind of medicinal composition for treating pullorum and preparation method thereof | |
| CN104161817B (en) | A kind of compound traditional Chinese medicine composite for preventing and treating chicken bacterial disease and preparation method thereof | |
| CN113559137A (en) | Granulating method of veterinary drug granules | |
| CN101664485A (en) | Traditional Chinese medicine for treating respiratory disease of livestock and preparation method thereof | |
| CN113209011A (en) | Traditional Chinese medicine oral liquid for preventing and treating porcine viral diarrhea diseases and preparation method and application thereof | |
| CN106177079A (en) | A kind of Chinese medicine composition treating respiratory disease of chicken and preparation method thereof | |
| CN120093846B (en) | A Chinese medicine composition for preventing and treating lung heat, cough and asthma in livestock, and its preparation method and application | |
| CN114366770A (en) | Preparation method of Qiqing Baidu granules | |
| CN104162074B (en) | A kind of veterinary Chinese medicinal composition and preparation method for being used to treat respiratory infectious disease | |
| CN115607594B (en) | A Chinese medicine composition for preventing and treating necrotic enteritis in poultry and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200221 |
|
| RJ01 | Rejection of invention patent application after publication |